SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION, BP SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

SULFAMETHOXAZOLE; TRIMETHOPRIM

Disponible desde:

JUNO PHARMACEUTICALS CORP.

Código ATC:

J01EE01

Designación común internacional (DCI):

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Dosis:

80MG; 16MG

formulario farmacéutico:

SOLUTION

Composición:

SULFAMETHOXAZOLE 80MG; TRIMETHOPRIM 16MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

100

tipo de receta:

Prescription

Resumen del producto:

Active ingredient group (AIG) number: 0208901005; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2022-08-30

Ficha técnica

Page 1 of 41
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION, BP
sulfamethoxazole (80 mg/mL) + trimethoprim (16 mg/mL)
sterile solution for the preparation of intravenous infusions
ANTIBACTERIAL AGENT
Juno Pharmaceuticals Corp
402-2233 Argentia Road,
Mississauga, ON, L5N 2X7
Control Number: 258006
Date of Preparation: August 18, 2022
Page 2 of 41
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES ..........................................
Error! Bookmark not defined.
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (2 months – 12 years of age)
.............................................................. 5
1.2
Geriatrics
............................................................................................................
5
2
CONTRAINDICATIONS
...............................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..................................................... 6
4
DOSAGE AND ADMINISTRATION
..............................................................................
6
4.1
Dosing Considerations
........................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
.................................................... 6
4.3
Reconstitution
.....................................................................................................
8
4.4
Administration
.....................................................................................................
9
5
OVERDOSAGE
............................................................................................................
9
6
DOSAGE FORMS, STRE